BVS Bioventus Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BVS

Price (delayed)

$11.8

Market cap

$985.71M

P/E Ratio

27.44

Dividend/share

N/A

EPS

$0.43

Enterprise value

$1.22B

?
Relative Growth: Rel. Growth: 57
Relative Strength: Rel. Strength: 89
Relative Valuation: Rel. Valuation: 80
Relative Profitability: Rel. Profitability: 87

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations ...

Highlights
The company's net income has surged by 184% YoY and by 25% QoQ
Bioventus's EPS has soared by 183% YoY and by 26% from the previous quarter
The quick ratio rose by 31% year-on-year but it has declined by 5% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.bioventus.com
Peers: OFIX

Key stats

What are the main financial stats of BVS

BVS stock price

How has the Bioventus stock price performed over time
Intraday
2.79%
1 week
-2.16%
1 month
24.21%
1 year
84.38%
YTD
58.6%
QTD
25%

Financial performance

How have Bioventus's revenue and profit performed over time
Revenue
$576.3M
Gross profit
$395.87M
Operating income
$33.56M
Net income
$28.48M
Gross margin
68.7%
Net margin
4.9%
The company's net income has surged by 184% YoY and by 25% QoQ
BVS's net margin has soared by 182% YoY and by 23% QoQ
The operating income has soared by 168% YoY and by 31% from the previous quarter
Bioventus's operating margin has surged by 167% YoY and by 29% QoQ

Price vs fundamentals

How does BVS's price correlate with its fundamentals

Growth

What is Bioventus's growth rate over time

Valuation

What is Bioventus stock price valuation
P/E
27.44
P/B
5.19
P/S
1.38
EV/EBIT
24.01
EV/EBITDA
12.57
EV/Sales
2.12
Bioventus's EPS has soared by 183% YoY and by 26% from the previous quarter
BVS's price to book (P/B) is 79% more than its 5-year quarterly average of 2.9 and 48% more than its last 4 quarters average of 3.5
Bioventus's equity has increased by 28% YoY and by 2.6% from the previous quarter
BVS's P/S is 53% above its 5-year quarterly average of 0.9 and 53% above its last 4 quarters average of 0.9

Efficiency

How efficient is Bioventus business performance
The return on assets has surged by 193% year-on-year and by 27% since the previous quarter
The ROE has soared by 172% year-on-year and by 18% since the previous quarter
The return on invested capital has increased by 12% since the previous quarter
Bioventus's ROS has increased by 4.8% from the previous quarter

Dividends

What is BVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BVS.

Financial health

How did Bioventus financials performed over time
Bioventus's total assets is 56% more than its total liabilities
The quick ratio rose by 31% year-on-year but it has declined by 5% since the previous quarter
Bioventus's total liabilities has decreased by 18% YoY and by 9% QoQ
BVS's debt is 44% higher than its equity
BVS's debt to equity is down by 38% year-on-year and by 10% since the previous quarter
Bioventus's equity has increased by 28% YoY and by 2.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.